Alfuzosin

Alfuzosin

Systematic (IUPAC) name
N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
Clinical data
Trade names	Uroxatral
AHFS/Drugs.com	monograph
MedlinePlus	a604002
Pregnancy cat.	B2 (AU) B (US)
Legal status	POM (UK) ℞-only (US)
Routes	Oral
Pharmacokinetic data
Bioavailability	49%
Protein binding	82%-90%
Metabolism	Hepatic (CYP3A4-mediated)
Half-life	10 hours
Excretion	Fecal (69%) and renal (24%)
Identifiers
CAS number	81403-80-7 Y
ATC code	G04CA01
PubChem	CID 2092
DrugBank	DB00346
ChemSpider	2008 Y
UNII	90347YTW5F Y
KEGG	D07124 Y
ChEBI	CHEBI:51141 Y
ChEMBL	CHEMBL709 Y
Chemical data
Formula	C19H27N5O4
Mol. mass	389.449 g/mol
SMILES O=C(NCCCN(c2nc1cc(OC)c(OC)cc1c(n2)N)C)C3OCCC3
InChI InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23) Y Key:WNMJYKCGWZFFKR-UHFFFAOYSA-N Y
Y (what is this?)  (verify)

Alfuzosin (INN, provided as the hydrochloride salt) is an α₁ receptor antagonist used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate.

Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral and elsewhere under the tradename Xatral, and in Egypt under name of Prostetrol. Alfuzosin was approved by the FDA for treatment of BPH in June 2003.

Side effects

The most common side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.

Contraindications

Alfuzosin should be used with caution in patients with severe renal insufficiency, and should not be prescribed to patients with a known history of QT prolongation who are taking medications known to prolong the QT interval.

External links

• Uroxatral (manufacturer's website)
• Alfuzosin (patient information)
• Sandoz Alfuzosin (Canadian product sheet)
• Alfuzosin (General information from the NIH)